These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
141 related articles for article (PubMed ID: 24021785)
1. [Clinical features of antiviral therapy-induced thyroid disease in patients with chronic hepatitis C]. Liu JP; Hou HR; Kang Y; Shang J; Cao YG; Liang SQ; Jin X Zhonghua Gan Zang Bing Za Zhi; 2013 Apr; 21(4):257-60. PubMed ID: 24021785 [TBL] [Abstract][Full Text] [Related]
2. [Analysis of thyroid dysfunction and influencing factors in chronic hepatitis C patients treated with peg-IFNa-2a and ribavirin]. Huang YX; Chen XY; Ma LN; Yin JM; Ren S; Guo DD; Zheng YH Zhonghua Gan Zang Bing Za Zhi; 2012 Mar; 20(3):216-20. PubMed ID: 22475143 [TBL] [Abstract][Full Text] [Related]
3. Incidence of and risk factors for thyroid dysfunction during peginterferon α and ribavirin treatment in patients with chronic hepatitis C. Hwang Y; Kim W; Kwon SY; Yu HM; Kim JH; Choe WH Korean J Intern Med; 2015 Nov; 30(6):792-800. PubMed ID: 26552454 [TBL] [Abstract][Full Text] [Related]
4. Thyroid function and changes in ultrasound morphology during antiviral therapy with pegylated interferon and ribavirin in patients with chronic hepatitis C. Friedrich-Rust M; Theobald J; Zeuzem S; Bojunga J J Viral Hepat; 2009 Mar; 16(3):168-77. PubMed ID: 19175874 [TBL] [Abstract][Full Text] [Related]
5. [Efficacy of combination therapy with pegylated-interferon alfa-2a plus ribavirin in autoantibody-positive chronic hepatitis C patients]. Li YX; Yang YJ; Yang M; Chen LY; Lu JJ; Ma YJ; Liu K; Lei XZ; Tang H Zhonghua Gan Zang Bing Za Zhi; 2013 May; 21(5):345-7. PubMed ID: 24025134 [TBL] [Abstract][Full Text] [Related]
6. [Clinical observation of Hashimoto thyroiditis in patients with chronic hepatitis C undergoing pegylated-interferon alpha-2a and ribavirin combination therapy]. Teng ZL; Gong WJ; Zhang SQ; Sun YX; Ma XH Zhonghua Gan Zang Bing Za Zhi; 2013 Feb; 21(2):101-4. PubMed ID: 23663880 [TBL] [Abstract][Full Text] [Related]
7. [Efficacy of standard antiviral therapy retreatment following interferon treatment failure in chronic hepatitis C patients]. Liu JP; Kang Y; Shang J; Ding GQ; Xiao EH; Wei JF; Cao Q Zhonghua Gan Zang Bing Za Zhi; 2013 Sep; 21(9):656-8. PubMed ID: 24160338 [TBL] [Abstract][Full Text] [Related]
8. Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy. Chen TM; Huang PT; Tsai MH; Lin LF; Liu CC; Ho KS; Siauw CP; Chao PL; Tung JN J Gastroenterol Hepatol; 2007 May; 22(5):669-75. PubMed ID: 17444854 [TBL] [Abstract][Full Text] [Related]
9. Thyroid dysfunction in patients with chronic hepatitis C: virus- or therapy-related? Vezali E; Elefsiniotis I; Mihas C; Konstantinou E; Saroglou G J Gastroenterol Hepatol; 2009 Jun; 24(6):1024-9. PubMed ID: 19383078 [TBL] [Abstract][Full Text] [Related]
10. [The efficacy and prognostic predictors of different treatment courses with pegylated interferon α-2a and ribavirin combination in recurrent chronic hepatitis C patients]. Rao H; Yang R; Shang J; Xu X; Chen X; Dou X; Feng Y; Gao Z; Xie Q; Li J; You H; Chen G; Niu J; Gong G; Hou J; Chen H; Zhang D; Wei L Zhonghua Nei Ke Za Zhi; 2015 Aug; 54(8):699-704. PubMed ID: 26674626 [TBL] [Abstract][Full Text] [Related]
11. [Dynamic changes in PD-1, TLR3, and TLR4 surface expression on peripheral blood mononuclear cells in chronic hepatitis C patients undergoing peg-IFNalpha-2a plus ribavirin combination therapy]. Zhang M; Jiang YF; Xiao XQ; Liu SF; Peng ML; Liu D; Gong GZ Zhonghua Gan Zang Bing Za Zhi; 2013 Mar; 21(3):196-201. PubMed ID: 23967741 [TBL] [Abstract][Full Text] [Related]
12. The role of thyroid autoantibodies in the development of thyroid dysfunction in Taiwanese chronic hepatitis C patients with interferon-alpha and ribavirin combination therapy. Huang JF; Chuang WL; Dai CY; Chen SC; Lin ZY; Lee LP; Lee PL; Wang LY; Hsieh MY; Chang WY; Yu ML J Viral Hepat; 2006 Jun; 13(6):396-401. PubMed ID: 16842442 [TBL] [Abstract][Full Text] [Related]
13. [Association between ribavirin plasma concentration and sustained virologic response in treatment of patients with genotype 1b chronic hepatitis C with pegylated interferon-α-2b and ribavirin]. Wang MR; Zhang X; Yang ZG; Li P; Gao L; Chen XH; Wang J; Xiong X; Wang SM; Geng JB; Hao KY; Xie F; Wang M; Zheng WK Zhonghua Gan Zang Bing Za Zhi; 2016 Mar; 24(3):175-80. PubMed ID: 27095759 [TBL] [Abstract][Full Text] [Related]
14. [Short-term curative effect of ribavirin combination therapy with pegylated interferon alfa-2a vs. interferon alfa-2a in patients with chronic hepatitis C]. Wang M; Zheng W; Zhang H; Li Z; Jiang D; Liu Y; Zhou R; Li XG; Zhang Y; Zhang Z; Wu S; Zhang Y; Li J Zhonghua Gan Zang Bing Za Zhi; 2014 Apr; 22(4):255-9. PubMed ID: 25173222 [TBL] [Abstract][Full Text] [Related]
15. Coadministration of ezetimibe with pegylated interferon plus ribavirin could improve early virological response in chronic hepatitis C obese Egyptian patients. Helal GK; Gad MA; Abd-Ellah MF; Mahgoup EM Eur J Gastroenterol Hepatol; 2016 May; 28(5):553-7. PubMed ID: 26872109 [TBL] [Abstract][Full Text] [Related]
16. Pegylated interferon plus ribavirin combination therapy for chronic hepatitis C with high viral load of serum hepatitis C virus RNA, genotype 1b, discontinued on attaining sustained virological response at week 16 after onset of acute pancreatitis. Kim SR; Imoto S; Mita K; Taniguchi M; Sasase N; Muramatsu A; Kudo M; Kitai S; El-Shamy A; Hotta H; Hayashi Y Digestion; 2009; 79(1):36-9. PubMed ID: 19246919 [TBL] [Abstract][Full Text] [Related]
17. Predictive value of early virological response to treatment with different interferon-based regimens plus ribavirin in patients with chronic hepatitis C. Napoli N; Giannelli G; Parisi CV; Antonaci A; Maddalena G; Antonaci S New Microbiol; 2005 Jan; 28(1):13-21. PubMed ID: 15782622 [TBL] [Abstract][Full Text] [Related]
18. [Efficacy and safety of pegylated interferon α-2b injection (Y shape, 40 kD) in treatment of patients with genotype 1/6 chronic hepatitis C]. Feng B; Shang J; Wu SH; Chen H; Han Y; Li YQ; Zhang DZ; Zhao LF; Wei SF; Mao Q; Yin CB; Han T; Wang MR; Chen SJ; Li J; Xie Q; Zhen Z; Gao ZL; Zhang YX; Gong GZ; Yang DL; Pan C; Sheng JF; Tang H; Ning Q; Shi GF; Niu JQ; Luo GH; Sun YT; You H; Wang GQ; Zhang LL; Peng J; Zhang Q; Liu JJ; Chen CW; Chen XY; Zhao W; Wang RH; Sun L; Wei L Zhonghua Gan Zang Bing Za Zhi; 2017 Mar; 25(3):187-194. PubMed ID: 28482405 [No Abstract] [Full Text] [Related]
19. Serum interleukin-6 levels correlate with resistance to treatment of chronic hepatitis C infection with pegylated-interferon-α2b plus ribavirin. Ueyama M; Nakagawa M; Sakamoto N; Onozuka I; Funaoka Y; Watanabe T; Nitta S; Kiyohashi K; Kitazume A; Murakawa M; Nishimura-Sakurai Y; Sekine-Osajima Y; Itsui Y; Azuma S; Kakinuma S; Watanabe M; Antivir Ther; 2011; 16(7):1081-91. PubMed ID: 22024524 [TBL] [Abstract][Full Text] [Related]
20. [Association between the influential factors and the effectiveness of pegylated interferon alpha-2a plus ribavirin as a combination treatment for chronic hepatitis C patients]. He LL; Chen Z; Chen Y; Xu H; Tang H; Lei BJ; Lei XZ Zhonghua Gan Zang Bing Za Zhi; 2011 Jan; 19(1):34-7. PubMed ID: 21272456 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]